Research programme: Alzheimer's disease and Parkinsons disease therapies - Elan/DGT
Latest Information Update: 22 Sep 2006
At a glance
- Originator Digital Gene Technologies; Elan Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Parkinson's disease
Most Recent Events
- 27 Feb 2001 New profile
- 27 Feb 2001 Preclinical development for Alzheimer's disease in USA (Unknown route)
- 27 Feb 2001 Preclinical development for Parkinson's disease in USA (Unknown route)